Drugs / Human-derived stromal cells
Human-derived stromal cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07232147 | Dec 2025 → Oct 2027 expected | Parkinson disease, movement disorder, neurodegenerative disease | Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Human-derived stromal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07232147 ↗ |
| Known as | hUC-MSCs | “This study, through different administration methods, adopted a randomized, double-blind, placebo-controlled trial design to evaluate the safety and tolerability of human...” NCT07232147 ↗ |
| Known as | human umbilical cord mesenchymal stem cells | “This study, through different administration methods, adopted a randomized, double-blind, placebo-controlled trial design to evaluate the safety and tolerability of human...” NCT07232147 ↗ |
| Route | Intravenous | “administered intravenously once every two weeks” NCT07232147 ↗ |